Retatrutide and tirzepatide sound similar. But if you are comparing them, three details matter more than the biggest weight loss number in a headline.

Tirzepatide acts on GIP and GLP one receptors. Retatrutide also targets the glucagon receptor. That makes it a triple agonist, not simply a stronger version of the same medicine.

As checked in September twenty twenty-six, Lilly describes retatrutide as investigational and available only in its clinical trials. Tirzepatide has approved medicines in some markets. Local authorization still matters.

To compare two weight loss headlines, look at the people, the length of treatment and how the result was calculated. Separate trials do not tell you what the same person would experience on both treatments.

If you are searching in Bali, a product listing alone does not establish an approved medicine. Ask for the exact product name, manufacturer and local registration details before treating two offers as comparable.

The article below explains the differences and gives you a short question list to take into a weight management appointment. Start with the treatment goal and the available options.